Texas-based biotechnology company OncoNano Medicine, Inc. has raised an additional $23.7 million Series A funding round.

OncoNano Medicine secured the proceeds from Los Angeles-based investment bank and wealth management firm Salem Partners.

The company is planning to use the new capital to accelerate its cancer imaging clinical trials and support the expansion of its technology into candidates for therapeutic applications.

The latest financing round brings OncoNano Medicine's total equity funding raised to date to $35.4 million.